BioMarin Pharmaceutical Inc.
GB ˙ LSE ˙ US09061G1013
57,62 $ ↑1,19 (2,11%)
2026-06-05
DEL PRIS
SecurityGB:0HNC / BioMarin Pharmaceutical Inc.
InstitutionHighTower Advisors, LLC
Latest Disclosed Ownership47,276 shares
Latest Disclosed Value $ 2,670,621
HighTower Advisors, LLC ownership in 0HNC / BioMarin Pharmaceutical Inc.

On May 5, 2026 - HighTower Advisors, LLC filed a 13F-HR form disclosing ownership of 47,276 shares of BioMarin Pharmaceutical Inc. (GB:0HNC) valued at $2,633,273 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 48,032 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of -1.57% during the quarter. The current value of the position is $2,724,043 USD.

HighTower Advisors, LLC has a history of taking positions in derivatives of the underlying security (0HNC) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

GB:0HNC / BioMarin Pharmaceutical Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 47,276 -756 -1.57 2,671 -6.45 0.0028
2026-02-06 2025-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 48,032 5,502 12.94 2,855 23.93 0.0031
2025-11-07 2025-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 42,530 2,636 6.61 2,303 5.06 0.0026
2025-08-11 2025-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 39,894 -5,876 -12.84 2,193 -32.24 0.0027
2025-05-13 2025-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 45,770 4,302 10.37 3,235 18.72 0.0044
2025-02-07 2024-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 41,468 10,930 35.79 2,726 26.98 0.0037
2024-11-14 2024-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 30,538 27,843 1,033.14 2,146 879.91 0.0031
2024-08-13 2024-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,695 -4,454 -62.30 219 -65.02 0.0003
2024-05-06 2024-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 7,149 -1,111 -13.45 626 -21.85 0.0010
2024-02-12 2023-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 8,260 563 7.31 801 17.62 0.0013
2023-11-08 2023-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 7,697 2,776 56.41 681 58.74 0.0013
2023-08-14 2023-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,921 25 0.51 429 -10.25 0.0008
2023-05-12 2023-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,896 -217 -4.24 478 -9.30 0.0010
2023-02-09 2022-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 5,113 315 6.57 527 29.80 0.0012
2022-11-09 2022-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,798 -5,091 -51.48 406 -50.31 0.0011
2022-08-10 2022-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 9,889 -576 -5.50 817 1.11 0.0021
2022-05-12 2022-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 10,465 -10,346 -49.71 808 -56.18 0.0018
2022-02-10 2021-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 20,811 6,361 44.02 1,844 65.38 0.0040
2021-11-12 2021-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 14,450 9,939 220.33 1,115 194.97 0.0030
2021-08-06 2021-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,511 319 7.61 378 18.50 0.0011
2021-05-10 2021-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,192 179 4.46 319 -9.63 0.0010
2021-02-10 2020-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,013 4,013 353 0.0015
2020-11-13 2020-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -2,310 -100.00 0 -100.00
2020-08-10 2020-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,310 -88 -3.67 281 39.80 0.0015
2020-05-21 2020-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,398 -91 -3.66 201 -3.37 0.0013
2020-02-14 2019-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,489 2,489 208 0.0012
2019-11-12 2019-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -5,051 -100.00 0 -100.00
2019-08-13 2019-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 5,051 -970 -16.11 438 -18.13 0.0026
2019-05-15 2019-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 6,021 -133 -2.16 535 0.94 0.0036
2019-02-14 2018-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 6,154 1,057 20.74 530 7.51 0.0041
2018-11-09 2018-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 5,097 36 0.71 493 2.92 0.0036
2018-08-14 2018-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 5,061 1,801 55.25 479 81.44 0.0038
2018-05-15 2018-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 3,260 -533 -14.05 264 -22.12 0.0022
2018-02-14 2017-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 3,793 1,206 46.62 339 38.93 0.0028
2017-11-14 2017-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,587 -506 -16.36 244 -13.48 0.0021
2017-09-22 2017-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 3,093 3,093 282 0.0025
2017-08-14 2017-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 3,093 3,093 282
2016-08-11 2016-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -3,485 -100.00 0 -100.00
2016-05-16 2016-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 3,485 -1,724 -33.10 285 -48.46 0.0009
2016-05-18 2015-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 5,209 2,559 96.57 553 97.50 0.0066
2016-02-12 2015-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 5,209 553
2015-11-16 2015-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,650 2,650 0.00 280 0.0037
2015-05-15 2015-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -2,539 -100.00 0 -100.00
2015-02-17 2014-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,539 -695 -21.49 230 0.88 0.0035
2014-02-14 2013-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 3,234 3,234 228 0.0047
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-02-07 2024-12-31 13F BIOMARIN PHARMACEUTICAL COM Call 0 -100.00 0 n/a n/a n/a
2024-11-14 2024-09-30 13F BIOMARIN PHARMACEUTICAL COM Call 200 0 n/a n/a n/a
2022-11-09 2022-09-30 13F BIOMARIN PHARMACEUTICAL COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-08-10 2022-06-30 13F BIOMARIN PHARMACEUTICAL COM Call 400 4 n/a n/a n/a
2020-08-10 2020-06-30 13F BIOMARIN PHARMACEUTICAL COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-05-21 2020-03-31 13F BIOMARIN PHARMACEUTICAL COM Call 500 0.00 2 -33.33 n/a n/a n/a
2020-02-14 2019-12-31 13F BIOMARIN PHARMACEUTICAL COM Call 500 3 n/a n/a n/a
2016-05-16 2016-03-31 13F BIOMARIN PHARMACEUTICAL COM Call 0 -100.00 0 n/a n/a n/a
2016-05-18 2015-12-31 13F/A BIOMARIN PHARMACEUTICAL COM Call 300 0 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2023-02-09 2022-12-31 13F BIOMARIN PHARMACEUTICAL COM Put 0 -100.00 0 n/a n/a n/a
2022-11-09 2022-09-30 13F BIOMARIN PHARMACEUTICAL COM Put 1 0 n/a n/a n/a
2022-05-11 2022-03-31 13F BIOMARIN PHARMACEUTICAL COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-02-10 2021-12-31 13F BIOMARIN PHARMACEUTICAL COM Put 5 4 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.